RSS-Feed abonnieren
DOI: 10.1055/s-0030-1258132
Solid-Phase Synthesis of Phosphonylated Peptides
Publikationsverlauf
Publikationsdatum:
09. Juli 2010 (online)
![](https://www.thieme-connect.de/media/synlett/201013/lookinside/thumbnails/10.1055-s-0030-1258132-1.jpg)
Abstract
We report the solid-phase syntheses of two series of phosphonylated peptides using Fmoc-protected amino acids. The peptides corresponded to regions containing phosphonylated Ser195 in the active site of butyrylcholinesterase and Tyr411 of human serum albumin. The phosphonylated Fmoc-protected amino acids were used in solid-phase peptide synthesis to prepare the peptides. Fmoc-serine and Fmoc-tyrosine with benzyl ester protection were treated with alkyl methylphosphonic monochloridates to phosphonylate the side-chain hydroxy groups. The phosphonylated peptides were designed to mimic the protein region after exposure of the proteins to organophosphorus agents.
Key words
organophosphonates - nerve agent - phosphonylated peptides - peptide synthesis - solid phase
- Supporting Information for this article is available online:
- Supporting Information
-
1a
Coupland R.Leins KR. Science 2005, 308: 1841 -
1b
Rosenstock R.Keifer M.Daniell WE.McConnell R.Claypoole K. Lancet 1991, 338: 223 -
2a
Duysen EG.Li B.Xie W.Schopfer LM.Anderson RS.Broomfield CA.Lockridge O.
J. Pharmacol. Exp. Ther. 2001, 299: 528 -
2b
Tuin AW.Mol MAE.van den Berg RM.Fidder A.van der Marel GA.Overkleeft HS.Noort D. Chem. Res. Toxicol. 2009, 22: 683 - 3
Berijani S.Assadi Y.Anbia M.Hosseini M.-RM.Aghaee E. J. Chromatogr. A. 2006, 1123: 1 - 4
Ashley JA.Lin C.-H.Wirsching P.Janda KD. Angew. Chem. Int. Ed. 1999, 38: 1793 -
5a
Li B.Schopfer LM.Hinrichs SH.Masson P.Lockridge O. Anal. Biochem. 2007, 361: 263 -
5b
Lockridge O.Masson P. Neurotoxicology 2000, 21: 113 - 6
Ding S.-J.Carr J.Carlson JE.Tong L.Xue W.Li Y.Schopfer LM.Li B.Nachon F.Asojo O.Thompson CM.Hinrichs SH.Masson P.Lockridge O. Chem. Res. Toxicol. 2008, 21: 1787 -
7a
Attard TJ.O’Brien-Simpson N.Reynolds EC.
Int. J. Pept. Res. Ther. 2007, 13: 447 -
7b
McMurray JS.Coleman DR.Wand W.Campbell ML. Biopolymers 2001, 60: 3 -
8a
Harris PWR.Williams GM.Shepherd P.Brimble MA. Int. J. Pept. Res. Ther. 2008, 14: 387 -
8b
Hoffmann R.Hoffmann T.Tholey A.Schulte AC. J. Peptide Res. 1997, 49: 163 -
8c
Hoffmann R.Tholey A.Hoffmann T.Kalbitzer HR. Int. J. Peptide Protein Res. 1996, 47: 245 -
8d
Kupihár Z.Kele Z.Tóth GK. Org. Lett. 2001, 3: 1033 -
8e
Wijkmans JCHM.Meeuwenoord NJ.Bloemhoff W.van der Marel GA.van Boom JH. Tetrahedron 1996, 52: 2103 -
9a
Amitai G.Adani R.Yacov G.Yishay S.Teitlboim S.Tveria L.Limanovich O.Kushnir M.Meshulam H. Toxicology 2007, 233: 187 -
9b
Briseño-Roa L.Hill J.Notman S.Sellers D.Smith AP.Timperley CM.Wetherell J.Williams NH.Williams GR.Fersht AR.Griffiths AD. J. Med. Chem. 2006, 49: 246 - 10
Huang Y.Dey S.Zhang X.Sönnischen F.Garner P. J. Am. Chem. Soc. 2004, 126: 4626 - 11
Williams NH.Harrison JM.Read RW.Black RM. Arch. Toxicol. 2007, 81: 627 - 12
Bennett KD.Stensballe A.Podtelejnikov AV.Moniatte M.Jensen ON. J. Mass Spectrom. 2002, 37: 179 - 13
Attard TJ.O’Brien-Simpson NM.Reynolds EC. Int. J. Pept. Res. Ther. 2009, 15: 69